Table 3.
A summary of clinical trials of bispecific antibodies for relapsed/refractory AML (RR-AML). BiTE: bispecific T-cell engager, DART: dual-affinity retargeting molecule, ICI: immune checkpoint inhibitor, CR: complete remission, CRi: CR with incomplete hematologic recovery, CRS: cytokine releasing syndrome.
| Author | Object | Agent(s) | Class | Targets | Phase | Clinical Outcome | |
|---|---|---|---|---|---|---|---|
| Ravandi, et al., 2018 |
RR-AML | AMG330 | BiTE | CD33 and CD3 | I | CR/CRi CRS |
11.4% (4 of 35) 42.1% (15 of 35) |
| Eissenberg, et al., 2018 |
RR-AML | AMV564 | BiTE | CD33 and CD3 | I | CR/CRi CRS |
66.7% (12 of 18) 5.7% (1 of 18) |
| Ravandi, et al., 2018 |
RR-AML | XmAb14045 | BiTE | CD123 and CD3 | I | CR/CRi CRS |
23.1% (3 of 13) 77.9% (49 of 63) |
| Uy, et al., 2018 |
RR-AML | Flotetuzumab | DART | CD123 and CD3 | I/II | CR/CRi Severe CRS |
18.5% (5 of 27) 13.4% (4 of 30) |
| Wei, et al., 2019 |
RR-AML | Flotetuzumab +MGA012 |
DART+ ICI | CD123 and CD3 plus PD-1 |
I | Not reported | |